Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models.

TitleTherapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models.
Publication TypeJournal Article
Year of Publication2014
AuthorsKim H-J, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM-Y, Finkbeiner S, Gitler AD, Bonini NM
JournalNat Genet
Volume46
Issue2
Pagination152-60
Date Published2014 Feb
ISSN1546-1718
KeywordsAdenine, Amyotrophic Lateral Sclerosis, Analysis of Variance, Animals, Ataxins, DNA-Binding Proteins, Drosophila melanogaster, Eukaryotic Initiation Factor-2, Gene Ontology, High-Throughput Screening Assays, Humans, Immunoblotting, Immunohistochemistry, Indoles, Luminescent Proteins, Motor Neurons, Nerve Tissue Proteins, Phosphorylation, Poly(A)-Binding Proteins, Retina, RNA Interference, Saccharomyces cerevisiae, Saccharomyces cerevisiae Proteins, Small Molecule Libraries, Spinal Cord
Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal, late-onset neurodegenerative disease primarily affecting motor neurons. A unifying feature of many proteins associated with ALS, including TDP-43 and ataxin-2, is that they localize to stress granules. Unexpectedly, we found that genes that modulate stress granules are strong modifiers of TDP-43 toxicity in Saccharomyces cerevisiae and Drosophila melanogaster. eIF2α phosphorylation is upregulated by TDP-43 toxicity in flies, and TDP-43 interacts with a central stress granule component, polyA-binding protein (PABP). In human ALS spinal cord neurons, PABP accumulates abnormally, suggesting that prolonged stress granule dysfunction may contribute to pathogenesis. We investigated the efficacy of a small molecule inhibitor of eIF2α phosphorylation in ALS models. Treatment with this inhibitor mitigated TDP-43 toxicity in flies and mammalian neurons. These findings indicate that the dysfunction induced by prolonged stress granule formation might contribute directly to ALS and that compounds that mitigate this process may represent a novel therapeutic approach.

DOI10.1038/ng.2853
Alternate JournalNat. Genet.
PubMed ID24336168
PubMed Central IDPMC3934366
Grant ListR01NS073660 / NS / NINDS NIH HHS / United States
P01 AG032953 / AG / NIA NIH HHS / United States
DP2 OD004417 / OD / NIH HHS / United States
P30 AG010124 / AG / NIA NIH HHS / United States
AG10124 / AG / NIA NIH HHS / United States
P01 AG017586 / AG / NIA NIH HHS / United States
R01 NS039074 / NS / NINDS NIH HHS / United States
AG32953 / AG / NIA NIH HHS / United States
P50 NS053488 / NS / NINDS NIH HHS / United States
AG17586 / AG / NIA NIH HHS / United States
NS53488 / NS / NINDS NIH HHS / United States
DP2OD004417 / OD / NIH HHS / United States
/ / Howard Hughes Medical Institute / United States
R01NS065317 / NS / NINDS NIH HHS / United States
R01 NS065317 / NS / NINDS NIH HHS / United States
R01 NS073660 / NS / NINDS NIH HHS / United States